Paper20437015
Advanced-stage III/IV follicular lymphoma: treatment strategies for individual patients.
Heinzelmann F and 5 others. Strahlenther Onkol, 2010. Cited by 10 papers, by iCite.
Cite this record
ConductScience Library. Advanced-stage III/IV follicular lymphoma: treatment strategies for individual patients. Papers, record 20437015. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20437015
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Lymphoma, Follicular | Major topic |
| Antibodies, Monoclonal | |
| Antibodies, Monoclonal, Murine-Derived | |
| Combined Modality Therapy | |
| Humans | |
| Neoplasm Staging | |
| Radioimmunotherapy | |
| Rituximab | |
| Survival Rate |
Source PubMed
References86
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 12652459 | First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma. | Semin Oncol | 2003 | https://conductscience.org/library/papers/12652459 | PubMed |
| 2 | 12969983 | BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. | Blood | 2004 | https://conductscience.org/library/papers/12969983 | PubMed |
| 3 | 15453924 | Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. | Clin Lymphoma | 2004 | https://conductscience.org/library/papers/15453924 | PubMed |
| 4 | 10717153 | Radiobiological and Clinical Bases for Total Body Irradiation in the Leukemias and Lymphomas. | Semin Radiat Oncol | 1995 | https://conductscience.org/library/papers/10717153 | PubMed |
| 5 | 16230674 | New treatment options have changed the survival of patients with follicular lymphoma. | J Clin Oncol | 2005 | https://conductscience.org/library/papers/16230674 | PubMed |
| 6 | 16732818 | Value of low-dose 2 x 2 Gy palliative radiotherapy in advanced low-grade non-Hodgkin's lymphoma. | Australas Radiol | 2006 | https://conductscience.org/library/papers/16732818 | PubMed |
| 7 | 12663713 | Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma. | J Clin Oncol | 2003 | https://conductscience.org/library/papers/12663713 | PubMed |
| 8 | 16123223 | Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. | Blood | 2005 | https://conductscience.org/library/papers/16123223 | PubMed |
| 9 | 9060552 | Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. | J Clin Oncol | 1997 | https://conductscience.org/library/papers/9060552 | PubMed |
| 10 | 12036859 | Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. | Blood | 2002 | https://conductscience.org/library/papers/12036859 | PubMed |
| 11 | 15925981 | Analysis of local control in patients with non-Hodgkin's lymphoma according to the WHO classification. | Strahlenther Onkol | 2005 | https://conductscience.org/library/papers/15925981 | PubMed |
| 12 | 17488686 | Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). | Haematologica | 2007 | https://conductscience.org/library/papers/17488686 | PubMed |
| 13 | 11516864 | A high and sustained response rate in refractory or relapsing low-grade lymphoma masses after low-dose radiation: analysis of predictive parameters of response to treatment. | Int J Radiat Oncol Biol Phys | 2001 | https://conductscience.org/library/papers/11516864 | PubMed |
| 14 | 15684317 | Meta-analysis to evaluate the role of interferon in follicular lymphoma. | J Clin Oncol | 2005 | https://conductscience.org/library/papers/15684317 | PubMed |
| 15 | 8201380 | Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. | J Clin Oncol | 1994 | https://conductscience.org/library/papers/8201380 | PubMed |
| 16 | 15592494 | Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. | Bone Marrow Transplant | 2005 | https://conductscience.org/library/papers/15592494 | PubMed |
| 17 | 8049425 | Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. | Blood | 1994 | https://conductscience.org/library/papers/8049425 | PubMed |
| 18 | 12702528 | Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma. | Ann Oncol | 2003 | https://conductscience.org/library/papers/12702528 | PubMed |
| 19 | 18559872 | Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. | J Clin Oncol | 2008 | https://conductscience.org/library/papers/18559872 | PubMed |
| 20 | 16873669 | Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. | Blood | 2006 | https://conductscience.org/library/papers/16873669 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 37711166 | A rare case of follicular lymphoma of the bladder. | Urol Case Rep | 2023 | https://conductscience.org/library/papers/37711166 | PubMed |
| 28816963 | Efficacy and safety evaluation of fludarabine-based chemotherapy regimen for patients with non-Hodgkin lymphoma: A meta-analysis. | Medicine (Baltimore) | 2017 | https://conductscience.org/library/papers/28816963 | PubMed |
| 22430608 | Comparison on therapeutic effects of RFT and RCTVP regimen in the treatment of patients with indolent B-cell lymphoma in China. | Med Oncol | 2012 | https://conductscience.org/library/papers/22430608 | PubMed |
| 22349634 | Radiotherapy in stage I-III follicular non-Hodgkin lymphoma. Retrospective analysis of a series of 50 patients. | Strahlenther Onkol | 2012 | https://conductscience.org/library/papers/22349634 | PubMed |
| 21603989 | Interobserver variability of clinical target volume delineation in supra-diaphragmatic Hodgkin's disease: a multi-institutional experience. | Strahlenther Onkol | 2011 | https://conductscience.org/library/papers/21603989 | PubMed |
| 21544528 | Feasibility and toxicity of concomitant radio/immunotherapy with MabThera (Rituximab®) for patients with non-Hodkin's Lymphoma: results of a prospective phase I/II study. | Strahlenther Onkol | 2011 | https://conductscience.org/library/papers/21544528 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/20437015
GET https://conductscience.org/api/papers/v1/20437015/references?page=2